$IMRX Up 28%! 🚀 🔹 Immuneering ripping after fresh pancreatic cancer trial data caught serious attention 📈 🔹 Company reported 17.3 months median overall surv

$IMRX Up 28%! 🚀 🔹 Immuneering ripping after fresh pancreatic cancer trial data caught serious attention 📈 🔹 Company reported 17.3 months median overall survival in first-line metastatic pancreatic cancer patients treated with atebimetinib + chemotherapy 🔥 🔹 Atebimetinib targets the MAPK pathwa…